Quince Therapeutics, Inc. beat EPS estimates 100% of the time across 2 reported quarters (2 beats, 0 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-33.26 | $-12.31 | +63.0% | Beat |
| Q22026 FY2026 | $-33.26 | $68.00 | +304.4% | Beat |
| Q12026 FY2026 | — | $-0.59 | — | Miss |
Back to QNCX overview · QNCX holders · QNCX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.